NCT03983096View on ClinicalTrials.gov

Pegylated Liposomal Doxorubicin or Epirubicin in Neoadjuvant or Adjuvant Chemotherapy for Breast Cancer.

CompletedOBSERVATIONAL
Enrollment

1,213

Participants

Timeline

Start Date

July 7, 2019

Primary Completion Date

May 1, 2020

Study Completion Date

May 1, 2020

Conditions
Breast Cancer
Trial Locations (1)

300000

Jin Zhang, Tianjin

Sponsors
All Listed Sponsors
collaborator

CSPC Ouyi Pharmaceutical Co., Ltd.

INDUSTRY

lead

Tianjin Medical University Cancer Institute and Hospital

OTHER